Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment.
Researchers have developed a mouse model that illuminates this problematic process, known as histological transformation. The findings advance the understanding of how mutated genes can trigger cancer evolution and suggest targets for more effective treatments.
The researchers, whose results were published in Science, discovered that during the transition from lung adenocarcinoma to small cell lung cancer (SCLC), the mutated cells appeared to undergo a change in cell identity through an intermediate, stem cell-like state, which facilitated the transformation.
“It is very difficult to study this process in human patients. So my aim was to uncover the mechanism underlying the transformation of lung adenocarcinoma to small cell lung cancer in a mouse model,” said the study lead. The complex mouse model took several years to develop and characterize but has allowed the researchers to crack this difficult problem.
“It is well known that cancer cells continue to evolve, especially to escape the pressure of effective treatments,” said the senior author. “This study shows how new technologies—including the detection of molecular features of single cancer cells, combined with computer-based analysis of the data—can portray dramatic, complex events in the evolution of lethal cancers, exposing new targets for therapeutic attack.”
SCLC most commonly occurs in heavy smokers, but this type of tumor also develops in a significant number of patients with lung adenocarcinomas, particularly after treatment with therapies that target a protein called Epidermal Growth Factor Receptor (EGFR), which promotes tumor growth. The new SCLC-type tumors are resistant to anti-EGFR therapy because their growth is fueled by a new cancer driver, high levels of Myc protein.
To unravel the interplay of these cancer pathways, the researchers engineered mice to develop a common form of lung adenocarcinoma, in which lung epithelial cells are driven by a mutated version of the EGFR gene. They then turned the adenocarcinoma tumors into SCLC-type tumors, which generally arise from neuroendocrine cells. They did this by shutting off EGFR in the presence of several other changes including losses of the tumor suppressor genes Rb1 and Trp53 as well as turning up the production of Myc, a known driver of SCLC.
Oncogenes, such as EGFR and Myc, are mutated forms of genes that normally control cell growth. They are known for their roles in driving the growth and spread of cancer. Tumor suppressor genes, on the other hand, normally inhibit cell proliferation and tumor development.
Surprisingly, this study showed that oncogenes act in a context-dependent manner. While most lung cells are resistant to becoming cancerous by Myc, neuroendocrine cells, are very sensitive to the oncogenic effects of Myc. Conversely, epithelial cells, which line the air sacs of the lungs and are the precursors to lung adenocarcinomas, grow excessively in response to mutated EGFR.
“This shows that an ‘oncogene’ in the wrong cell type doesn’t act like an oncogene anymore,” the author said. “So, it fundamentally changes how we think about oncogenes.”
The researchers also discovered a stem cell-like intermediate that was neither adenocarcinoma nor SCLC. Cells in this transitional state became neuroendocrine in nature only when mutations in the tumor suppressor genes RB1 and TP53 were present. They observed that loss of another tumor suppressor called Pten accelerated this process. At that stage, oncogenic Myc could drive these intermediate stem-like cells to form SCLC-type tumors.
This study further supports efforts seeking therapeutics that target Myc proteins, which are implicated in many types of cancers. The researchers now plan to use their new mouse model to further explore the adenocarcinoma-SCLC transition, detailing, for example, how the immune system normally responds to this transition.
Latest News
Protease action on controll…
By newseditor
Posted 25 May
Maternal inflammation activ…
By newseditor
Posted 25 May
How cells deal with extra c…
By newseditor
Posted 25 May
Flicker stimulation modulat…
By newseditor
Posted 25 May
Multi-dose TB vaccines prot…
By newseditor
Posted 24 May
Other Top Stories
CRISPR-based test for COVID-19 uses a smartphone camera
Read more
How COVID-19 virus causes multiple organ failure in mice
Read more
A leukemia patient sheds infectious SARS-CoV-2 for at least 70 days
Read more
A host factor that helps viruses replicate and infect other cells i…
Read more
Gut microbiota act via endocannabinoid system to regulate depressiv…
Read more
Protocols
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Publications
Cryo-EM reveals that iRhom2…
By newseditor
Posted 25 May
Fetal brain response to mat…
By newseditor
Posted 25 May
Children born after assiste…
By newseditor
Posted 25 May
Macrophage-induced integrin…
By newseditor
Posted 25 May
Copy number alterations: a…
By newseditor
Posted 25 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar